. Author manuscript; available in PMC: 2014 Nov 1.

Published in final edited form as: Eur Neuropsychopharmacol. 2013 May 9;23(11):10.1016/j.euroneuro.2013.03.003. doi: 10.1016/j.euroneuro.2013.03.003

Table 2.

Clinical ratings in eventual antidepressant treatment responders and non-responders at baseline and 12 weeks post-treatment as well as clinical ratings changes (mean ± standard deviation)

	Baseline		Week 12		Rating change (%) from baseline to week 12

Clinical Measures	Responder (N=26)	Non- Responder (N=25)	Responder (N=26)	Non- Responder (N=25)	Responder (N=26)	Non- Responder (N=24)
HAMD₁₇	19.6 ± 5.9	21.6 ± 3.5	4.4 ± 3.2	17.7 ± 6.5	−75.8% ± 18.4	−16.7% ± 28
MADRS	29.4 ± 4.5	31.9 ± 5.8	5.9 ± 4.9	26.5 ± 9.1	−80.0% ± 16.6	−16.9% ± 24.2

HAMD₁₇: Hamilton Rating Scale for Depression, 17 item version

MADRS: Montgomery-Åsberg Depression Rating Scale